Literature DB >> 28891040

Dosimetry in clinical radionuclide therapy: the devil is in the detail.

Francesco Giammarile1,2, Kristoff Muylle3,4, Roberto Delgado Bolton3,5, Jolanta Kunikowska3,6, Uwe Haberkorn7,8,9, Wim Oyen3,10.   

Abstract

Mesh：

Year:  2017        PMID： 28891040     DOI： 10.1007/s00259-017-3820-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  8 in total

Review 1.  General aspects of the cellular response to low- and high-LET radiation.

Authors:  J P Pouget; S J Mather
Journal:  Eur J Nucl Med       Date:  2001-04

2.  Individual susceptibility to radiosensitivity and to genomic instability: its impact on low-dose phenomena.

Authors:  Adeline Granzotto; Clément Devic; Muriel Viau; Mira Maalouf; Aurélie Joubert; Catherine Massart; Charles Thomas; Nicolas Foray
Journal:  Health Phys       Date:  2011-03       Impact factor: 1.316

3.  The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy.

Authors:  C Chiesa; K Sjogreen Gleisner; G Flux; J Gear; S Walrand; K Bacher; U Eberlein; E P Visser; N Chouin; M Ljungberg; M Bardiès; M Lassmann; L Strigari; M W Konijnenberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-24       Impact factor: 9.236

Review 4.  Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing.

Authors:  G L DeNardo; M E Juweid; C A White; G A Wiseman; S J DeNardo
Journal:  Crit Rev Oncol Hematol       Date:  2001 Jul-Aug       Impact factor: 6.312

5.  Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.

Authors:  Marie Boyd; Susan C Ross; Jennifer Dorrens; Natasha E Fullerton; Ker Wei Tan; Michael R Zalutsky; Robert J Mairs
Journal:  J Nucl Med       Date:  2006-06       Impact factor: 10.057

6.  Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment.

Authors:  Mattias Sandström; Ulrike Garske-Román; Dan Granberg; Silvia Johansson; Charles Widström; Barbro Eriksson; Anders Sundin; Hans Lundqvist; Mark Lubberink
Journal:  J Nucl Med       Date:  2012-12-07       Impact factor: 10.057

7.  Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study.

Authors:  Gillian C Barnett; Charlotte E Coles; Rebecca M Elliott; Caroline Baynes; Craig Luccarini; Don Conroy; Jennifer S Wilkinson; Jonathan Tyrer; Vivek Misra; Radka Platte; Sarah L Gulliford; Matthew R Sydes; Emma Hall; Søren M Bentzen; David P Dearnaley; Neil G Burnet; Paul D P Pharoah; Alison M Dunning; Catharine M L West
Journal:  Lancet Oncol       Date:  2011-12-12       Impact factor: 41.316

Review 8.  Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".

Authors:  B Brans; L Bodei; F Giammarile; O Linden; M Luster; W J G Oyen; J Tennvall
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05       Impact factor: 9.236
  8 in total
  7 in total

Review 1.  Perspectives for Concepts of Individualized Radionuclide Therapy, Molecular Radiotherapy, and Theranostic Approaches.

Authors:  Makoto Hosono
Journal:  Nucl Med Mol Imaging       Date:  2019-01-29

2.  Bone radionuclide therapy and increased survival with radium-223 is the way to go for nuclear medicine: the offer that oncologists cannot refuse.

Authors:  Roberto C Delgado Bolton; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-14       Impact factor: 9.236

3.  From fixed activities to personalized treatments in radionuclide therapy: lost in translation?

Authors:  G D Flux; K Sjogreen Gleisner; C Chiesa; M Lassmann; N Chouin; J Gear; M Bardiès; S Walrand; K Bacher; U Eberlein; M Ljungberg; L Strigari; E Visser; M W Konijnenberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-27       Impact factor: 9.236

Review 4.  Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review.

Authors:  Daphne Merel Valerie Huizing; Berlinda Jantina de Wit-van der Veen; Marcel Verheij; Marcellus Petrus Maria Stokkel
Journal:  EJNMMI Res       Date:  2018-08-29       Impact factor: 3.138

Review 5.  Radioimmunotherapy for Brain Metastases: The Potential for Inflammation as a Target of Choice.

Authors:  Aurélien Corroyer-Dulmont; Cyril Jaudet; Anne-Marie Frelin; Jade Fantin; Kathleen Weyts; Katherine A Vallis; Nadia Falzone; Nicola R Sibson; Michel Chérel; Françoise Kraeber-Bodéré; Alain Batalla; Stéphane Bardet; Myriam Bernaudin; Samuel Valable
Journal:  Front Oncol       Date:  2021-08-24       Impact factor: 5.738

6.  The internal dosimetry user group position statement on molecular radiotherapy.

Authors:  Jonathan Gear; Daniel McGowan; Bruno Rojas; Allison J Craig; April-Louise Smith; Catherine J Scott; James Scuffam; Matthew Aldridge; Jill Tipping
Journal:  Br J Radiol       Date:  2021-08-25       Impact factor: 3.629

7.  Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617.

Authors:  Jolanta Kunikowska; Ingeborga Charzyńska; Radosław Kuliński; Dariusz Pawlak; Michał Maurin; Leszek Królicki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-02-10       Impact factor: 9.236
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.